BOLD vs CRGO Comparison

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters, thousands of forwarders, and dozens of airlines and ocean carriers. The company operates in two segments: the Platform segment and the Solutions segment. The majority of the revenue is derived from the Solutions segment, which provides software tools and data to help industry participants automate their pricing, sales, and procurement processes. Geographically, it generates the maximum revenue from Europe, and the rest from the United States, Hong Kong and Others.